Business Description
Recce Pharmaceuticals Ltd
ISIN : AU000000RCE5
Description
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | -9.12 | |||||
Debt-to-Equity | -0.58 | |||||
Debt-to-EBITDA | -0.37 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -11.3 | |||||
3-Year EPS without NRI Growth Rate | -13.2 | |||||
3-Year FCF Growth Rate | -19 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 197.74 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.08 | |||||
Quick Ratio | 0.08 | |||||
Cash Ratio | 0.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.8 | |||||
Shareholder Yield % | -18.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -486.3 | |||||
ROIC % | -639.53 | |||||
3-Year ROIIC % | -750.1 | |||||
ROC (Joel Greenblatt) % | -2554.19 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -5.15 | |||||
EV-to-EBITDA | -5.21 | |||||
EV-to-Forward-Revenue | 20.69 | |||||
EV-to-FCF | -6.47 | |||||
Earnings Yield (Greenblatt) % | -19.42 | |||||
FCF Yield % | -16.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:RECEF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Recce Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.075 | ||
| Beta | -0.9389 | ||
| 3-Year Sharpe Ratio | -0.59 | ||
| 3-Year Sortino Ratio | -0.63 | ||
| Volatility % | 56 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 0.22 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.22 - 0.22 | ||
| Shares Outstanding (Mil) | 289.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Recce Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Recce Pharmaceuticals Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Recce Pharmaceuticals Ltd Frequently Asked Questions
What is Recce Pharmaceuticals Ltd(RECEF)'s stock price today?
The current price of RECEF is $0.22. The 52 week high of RECEF is $0.22 and 52 week low is $0.22.
When is next earnings date of Recce Pharmaceuticals Ltd(RECEF)?
The next earnings date of Recce Pharmaceuticals Ltd(RECEF) is .
Does Recce Pharmaceuticals Ltd(RECEF) pay dividends? If so, how much?
Recce Pharmaceuticals Ltd(RECEF) does not pay dividend.
Guru Commentaries on OTCPK:RECEF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Recce Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers